Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2022 | 2 |
2023 | 5 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6.
Lancet. 2023.
PMID: 36493791
Free article.
Clinical Trial.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC.
Merola JF, et al.
Lancet. 2023 Jan 7;401(10370):38-48. doi: 10.1016/S0140-6736(22)02303-0. Epub 2022 Dec 6.
Lancet. 2023.
PMID: 36495881
Free article.
Clinical Trial.
Item in Clipboard
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019.
Shin YH, Hwang J, Kwon R, Lee SW, Kim MS; GBD 2019 Allergic Disorders Collaborators; Shin JI, Yon DK.
Shin YH, et al.
Allergy. 2023 Aug;78(8):2232-2254. doi: 10.1111/all.15807. Epub 2023 Jul 11.
Allergy. 2023.
PMID: 37431853
Item in Clipboard
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewé RB.
Ritchlin CT, et al.
Ann Rheum Dis. 2023 Nov;82(11):1404-1414. doi: 10.1136/ard-2023-224431. Epub 2023 Sep 11.
Ann Rheum Dis. 2023.
PMID: 37696588
Free PMC article.
Clinical Trial.
Item in Clipboard
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019.
GBD 2019 IMID Collaborators.
GBD 2019 IMID Collaborators.
EClinicalMedicine. 2023 Sep 9;64:102193. doi: 10.1016/j.eclinm.2023.102193. eCollection 2023 Oct.
EClinicalMedicine. 2023.
PMID: 37731935
Free PMC article.
Item in Clipboard
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence.
Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M.
Wu JJ, et al.
Dermatol Ther (Heidelb). 2020 Jun;10(3):351-364. doi: 10.1007/s13555-020-00373-z. Epub 2020 Apr 2.
Dermatol Ther (Heidelb). 2020.
PMID: 32242325
Free PMC article.
Review.
Item in Clipboard
Cite
Cite